Litigation Details for Classen Immunotherapies, Inc. v. Shionogi, Inc. (Fed. Cir. 2014)

« Back to Dashboard

Classen Immunotherapies, Inc. v. Shionogi, Inc. (Fed. Cir. 2014)

Docket		Date Filed	2014-03-18
Court	Court of Appeals for the Federal Circuit	Date Terminated	2014-12-08
Cause		Assigned To
Jury Demand		Referred To
Patents	7,915,307
Link to Docket	External link to docket

Details for Classen Immunotherapies, Inc. v. Shionogi, Inc. (Fed. Cir. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-03-18				External link to document

Classen Immunotherapies v. Shionogi, Inc. (Fed. Cir. No. 14-1364): Litigation Summary and Patent-Eligibility Analysis

Last updated: November 2, 2026

Classen Immunotherapies, Inc. v. Shionogi, Inc., 803 F.3d 1326 (Fed. Cir. 2015), concerned whether Classen’s immunization-schedule claims were patent-eligible under 35 U.S.C. § 101. The Federal Circuit reversed the district court’s dismissal, holding that the asserted claims were directed to a specific immunization treatment method rather than an unpatentable natural law alone.

The decision preserved Classen’s ability to pursue infringement claims against Shionogi. It did not establish infringement, validate every Classen patent claim, resolve claim construction, or determine damages.

What was the Classen v. Shionogi dispute about?

Classen alleged that Shionogi infringed patents covering methods for identifying and using vaccination schedules associated with reduced risk of chronic immune-mediated disorders.

The technology combined two concepts:

1. Analysis of historical immunization data to identify a lower-risk vaccination schedule.
2. Immunization of patients according to the schedule identified through that analysis.

The asserted patent was U.S. Patent No. 6,420,139, generally directed to methods for identifying and evaluating vaccination schedules. The claims required more than merely recognizing a correlation between vaccination timing and disease risk. They included the practical use of the identified schedule in immunizing patients.

Shionogi challenged the complaint under Rule 12(b)(6), arguing that the claims were invalid under § 101 because they were directed to a natural law or an abstract mental process.

What did the district court decide?

The district court dismissed Classen’s claims at the pleading stage. It concluded that the asserted claims were directed to the relationship between immunization schedules and chronic immune-mediated disorders, which the court treated as a natural law.

The district court applied the two-step framework that had developed through Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012):

• First, determine whether the claims are directed to a law of nature, natural phenomenon, or abstract idea.
• Second, determine whether the claim contains an inventive concept sufficient to transform the ineligible concept into a patent-eligible application.

The district court viewed the data-analysis and comparison steps as insufficient to supply the required inventive concept.

How did the Federal Circuit rule in 803 F.3d 1326?

The Federal Circuit reversed and remanded.

The court held that the asserted claims were not directed solely to a natural law. They recited a treatment method that used the discovery of a risk relationship to select and administer a vaccination schedule.

The court emphasized the distinction between:

• A claim that merely identifies a natural relationship between vaccination schedules and disease risk; and
• A claim that applies that relationship by immunizing patients according to a schedule identified as presenting a lower risk.

The Federal Circuit treated the immunization step as material to the § 101 analysis. The claims were therefore directed to a specific method of treatment, not merely to the discovery or observation of a biological correlation.

What was the Federal Circuit’s core reasoning?

The court relied on the practical application of the claimed discovery. The asserted claims required the following sequence:

Claim element	Legal significance
Review multiple immunization schedules	Establishes the scope of the treatment-selection process
Compare disease incidence associated with the schedules	Uses clinical data to evaluate risk
Identify a schedule associated with lower risk	Converts the data into a treatment selection
Immunize patients according to the selected schedule	Applies the discovery in medical treatment

The final step distinguished the claims from a pure diagnostic or informational claim. The claimed method did not end with the discovery of a correlation. It used the correlation to direct patient care.

The decision did not hold that every method involving a vaccine or treatment is patent-eligible. Its holding turned on the claim language and the requirement to immunize according to the identified schedule. The Federal Circuit also did not hold that Classen’s patents were novel, nonobvious, enabled, or infringed.

Which patents and claims were involved?

The central patent was U.S. Patent No. 6,420,139, assigned to Classen Immunotherapies, Inc. The patent family covered methods for identifying and evaluating vaccination schedules and their relationship to chronic immune-mediated disorders.

Classen’s broader patent portfolio also included related vaccination-schedule patents, including U.S. Patent Nos. 6,638,739 and 6,783,739. The claims differed in scope and in whether they required actual immunization or only data analysis.

The Federal Circuit’s earlier decision in Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011), distinguished among Classen claims based in part on whether they required a treatment step. That distinction remained important in the Shionogi appeal.

Were all Classen vaccination-schedule claims upheld?

No. The Shionogi decision was claim-specific. The Federal Circuit did not declare the entire Classen patent estate valid.

Claims that required only collecting, comparing, or evaluating information faced greater § 101 risk. Claims requiring use of the identified schedule for immunization had a stronger eligibility position because they recited a treatment application.

What was the litigation timeline?

Date	Event
July 16, 2002	U.S. Patent No. 6,420,139 issued
2011	Federal Circuit addressed related Classen patent claims in Classen v. Biogen IDEC
2012	Supreme Court decided Mayo v. Prometheus, establishing the modern natural-law framework
2014	Classen appealed the district court’s dismissal in the Shionogi litigation
Oct. 30, 2015	Federal Circuit issued its decision in Classen v. Shionogi, 803 F.3d 1326
After Oct. 30, 2015	Case returned to the district court for further proceedings

The Federal Circuit appeal was docketed as No. 14-1364. The appellate decision addressed patent eligibility and did not resolve the merits of infringement or damages.

Did the Federal Circuit find Shionogi liable for infringement?

No.

The Federal Circuit reversed the dismissal based on § 101 and remanded the case. That ruling allowed Classen to continue litigating, but it did not establish:

• That Shionogi’s products practiced every claim limitation;
• That Shionogi had direct or induced infringement;
• That the claims were valid under §§ 102 and 103;
• That Classen was entitled to damages or an injunction.

A patent-eligibility ruling is not an infringement judgment. The decision removed an early pleading-stage barrier but left the substantive patent case unresolved.

What was the significance for method-of-use patent litigation?

The decision strengthened the position of treatment-method claims involving discovered biological relationships.

The ruling supports a drafting distinction:

Higher § 101 risk	Lower § 101 risk
Identifying a correlation between vaccination and disease	Selecting a vaccination schedule based on the correlation
Comparing patient data	Administering treatment according to the selected schedule
Reporting risk information	Applying the information to patient treatment
Generic data-processing language	Concrete treatment steps tied to a patient population

The decision did not eliminate Mayo-based challenges. Claims still require sufficient specificity and must avoid merely reciting conventional data collection, comparison, and reporting steps.

For pharmaceutical companies, the case supports the use of method-of-treatment claims as a complement to composition, formulation, and manufacturing claims. It also demonstrates that the treatment step should be drafted as an operative claim limitation rather than as an optional objective or intended use.

What was the Orange Book status of the Classen patents?

The Classen patents were not conventional Orange Book patents covering the active ingredient, dosage form, formulation, or manufacturing process of a prescription drug.

The asserted rights concerned vaccination schedules and treatment methods. They therefore did not operate like an Orange Book-listed patent that triggers a standard Abbreviated New Drug Application Paragraph IV certification.

The litigation was not a biosimilar dispute under the Biologics Price Competition and Innovation Act. It also was not a conventional generic-drug challenge directed to an NDA product’s active ingredient or formulation patent.

Did Shionogi face a Paragraph IV challenge?

No Paragraph IV issue was central to the Federal Circuit appeal. The dispute was an affirmative patent-infringement action involving method claims, not an ANDA-based patent certification proceeding.

A generic manufacturer could still face infringement risk if it induced performance of a patented vaccination method, but that risk would depend on the claim language, labeling, promotional conduct, and actual use of the vaccine. The Classen decision did not create automatic liability for vaccine manufacturers.

What generic-entry and biosimilar risks did the case create?

The immediate generic-entry risk was limited because Classen’s patents did not primarily protect a small-molecule active ingredient or drug formulation.

The relevant risk was method-of-use enforcement. Potential exposure could arise where a manufacturer:

• Labels a vaccine for a schedule covered by a Classen claim;
• Encourages healthcare providers to follow the patented schedule;
• Provides treatment protocols that direct use of the schedule;
• Receives a commercial benefit from the claimed immunization method.

Biosimilar risk was also limited. Vaccines and biologics may involve complex regulatory classifications, but the Classen decision did not concern a biosimilar application or the BPCIA patent-exchange process.

How strong was the Classen patent estate?

The estate had meaningful strategic value but material enforcement limitations.

Strengths

• The asserted claims included a concrete treatment step.
• The Federal Circuit rejected an early § 101 dismissal.
• The patent family addressed a clinically relevant relationship between vaccination timing and disease risk.
• The claims could potentially reach use of a vaccine even where the vaccine composition itself was not covered.

Weaknesses

• The technology depended heavily on claim wording.
• Data-only and correlation-only claims faced serious eligibility risk.
• Method claims required proof that the accused party practiced or induced the claimed schedule.
• The decision did not resolve novelty, obviousness, enablement, written description, or infringement.
• The patents were old relative to the 2015 appeal and had limited remaining term.

The strongest commercial claims were those that linked a defined patient population, a specific vaccination schedule, and administration of the vaccine according to that schedule.

Did the case affect licensing or settlement negotiations?

The Federal Circuit reversal improved Classen’s litigation leverage because it preserved the case after an early dismissal. It could support licensing discussions involving vaccine manufacturers, clinical-protocol providers, and entities controlling treatment guidelines.

The reported appellate decision did not disclose a licensing agreement, settlement payment, royalty rate, or commercial resolution between Classen and Shionogi. No specific settlement terms should be attributed to the case based on the Federal Circuit opinion.

What was the commercial impact and revenue exposure?

The opinion did not report Classen’s revenue, damages model, Shionogi product sales, royalty base, or market-share data.

Potential damages would have depended on proof of infringement, the remaining patent term, the number of covered vaccinations, the relevant product or service revenue, and whether Shionogi’s conduct supported direct or induced infringement. Because the claims focused on treatment scheduling rather than vaccine composition, a damages theory could have required careful apportionment between the value of the vaccine and the value of the claimed schedule.

What are the main legal takeaways from Classen v. Shionogi?

1. A treatment claim can remain eligible even when it relies on a naturally occurring biological relationship.
2. Actual administration of treatment can distinguish a patent-eligible method from a claim directed only to information.
3. The Federal Circuit’s ruling was limited to § 101.
4. The decision did not establish infringement or patent validity under other statutory provisions.
5. Vaccine-schedule patents may create method-of-use exposure without covering the vaccine composition.
6. Orange Book and Paragraph IV mechanisms generally do not apply to this type of standalone method patent.
7. Claim drafting should connect the discovered relationship to a defined treatment protocol.

Key Takeaways

• Classen Immunotherapies v. Shionogi, 803 F.3d 1326 (Fed. Cir. 2015), reversed a Rule 12(b)(6) dismissal based on patent ineligibility.
• The asserted claims covered identifying a lower-risk vaccination schedule and immunizing patients according to that schedule.
• The Federal Circuit treated the claims as a specific treatment method rather than a natural law in isolation.
• The decision did not determine infringement, damages, validity under §§ 102 or 103, or enforceability.
• The case had greater significance for method-of-treatment patent strategy than for generic, biosimilar, or Orange Book litigation.

FAQs About Classen Immunotherapies v. Shionogi

What patent was at issue in Classen v. Shionogi?

The principal patent was U.S. Patent No. 6,420,139, directed to methods for identifying and evaluating vaccination schedules associated with chronic immune-mediated disorders.

Did Classen win the entire case?

No. Classen won the Federal Circuit appeal on the narrow issue of patent eligibility. The court reversed the early dismissal and remanded the case. It did not enter an infringement judgment.

Did the ruling make vaccine-schedule patents automatically valid?

No. The ruling addressed only § 101 eligibility. The claims remained subject to novelty, obviousness, written-description, enablement, claim-construction, and infringement challenges.

Can a vaccine manufacturer infringe a method-of-use patent without owning the vaccine patent?

Yes, potentially. Liability can arise if the manufacturer directly practices the claimed method or induces others to perform it. The outcome depends on the claim language and the manufacturer’s labeling and conduct.

Is Classen v. Shionogi relevant to Orange Book patent listings?

Only indirectly. The case involved method-of-treatment patents rather than conventional patents covering an NDA drug’s active ingredient, formulation, dosage form, or manufacturing process. It was not a standard Paragraph IV litigation proceeding.

References

1. Classen Immunotherapies, Inc. v. Shionogi, Inc., 803 F.3d 1326 (Fed. Cir. 2015).

2. Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011).

3. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).

4. U.S. Patent No. 6,420,139. (2002). Methods and compositions for identifying and evaluating vaccination schedules. U.S. Patent and Trademark Office.

5. U.S. Patent No. 6,638,739. (2003). Methods and compositions for identifying and evaluating vaccination schedules. U.S. Patent and Trademark Office.